Cadila Healthcare on Wednesday said its subsidiary has received approval from the US health regulator to market Macitentan tablets, used to treat high blood pressure, in the American market.
Zydus Worldwide DMCC, a wholly owned subsidiary of the company, has received tentative approval from the US Food and Drug Administration (USFDA) to market Macitentan tablets, Cadila Healtcare said in a statement.
The tablets are indicated for treatment of pulmonary arterial hypertension and will be manufacturedat Vapi-based CMOUmedica Laboratories, it added.
The Zydus Cadila group now has 287 approvals and has so far filed over 386 abbreviated new drug applications since the commencement of the filing process in 2003-04, the company said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app